Pluri Inc. (PLUR) - 10-K Summary for Fiscal Year Ended June 30, 2025
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Pluri Inc. for the fiscal year ended June 30, 2025. Pluri is a biotechnology company leveraging a proprietary 3D cell expansion platform to develop scalable solutions in regenerative medicine, immunotherapy, food technology (FoodTech), agriculture technology (AgTech), and Contract Development and Manufacturing Organization (CDMO) services. The company operates primarily through its Israeli subsidiary, Pluri Biotech Ltd., and maintains a GMP-grade manufacturing facility in Haifa, Israel.
Key Financial Metrics
| Metric | Fiscal Year 2025 | Fiscal Year 2024 |
|---|---|---|
| Revenues | $1,336,000 | $326,000 |
| Cost of Revenues | $682,000 | $4,000 |
| Gross Profit | $654,000 | $322,000 |
| Net Loss | $(23,250,000) | $(21,344,000) |
| Loss Per Share (Basic & Diluted) | $(3.56) | $(3.99) |
| Cash and Cash Equivalents | $5,895,000 | $6,783,000 |
| Total Cash Resources (incl. deposits) | $21,914,000 | $31,107,000 (Current Assets) |
| Working Capital Deficit | $(10,233,000) | $26,653,000 (Surplus) |
| Accumulated Deficit | $(443,055,000) | $(420,472,000) |
Debt and Liquidity: The company holds a loan from the European Investment Bank (EIB) with a principal balance of approximately €20 million (reported as $23,459,000 principal plus accrued interest of $3,830,000 in current liabilities as of June 30, 2025). The loan is due on June 1, 2026. Management estimates insufficient resources to meet operating obligations for at least twelve months from the issuance date, raising substantial doubt about the company's ability to continue as a going concern.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 309% to $1.336 million, driven by higher CDMO service fees and AgTech proof-of-concept (POC) collaborations.
- Net Loss Increase: Net loss widened by approximately 9% to $23.25 million. The increase was primarily attributed to foreign exchange losses related to the EIB loan (Euro vs. USD fluctuations) and reduced interest income from deposits.
- Working Capital Shift: The company moved from a working capital surplus of $26.65 million in 2024 to a deficit of $10.23 million in 2025. This shift is largely due to the reclassification of the EIB loan to current liabilities as the maturity date (June 2026) approaches.
- Acquisition: Completed the acquisition of approximately 79% of Kokomodo Ltd. (cell-cultured cacao) in April 2025 for $4.5 million in stock, recording $2.823 million in intangible assets and $3.136 million in goodwill.
- Grant Termination: A $4.2 million contract with the U.S. NIAID for PLX-R18 development was terminated for the government's convenience in April 2025. The company received $2.3 million in funding prior to termination.
Guidance, Outlook, and Risks
Outlook: Management does not anticipate generating significant product revenues in the next twelve months. The company expects to continue incurring losses and requires additional capital to sustain operations and R&D. Initiatives to address liquidity include cost-reduction plans, seeking licensing deals, and finalizing EIB loan restructuring discussions.
Key Risks and Contingencies:
- Going Concern: The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
- EIB Loan Restructuring: The company is in advanced discussions with the EIB to restructure the loan terms, including an extension of the maturity date. Failure to reach an agreement could materially impact liquidity.
- Geopolitical Risk: Operations are concentrated in Haifa, Israel. Ongoing regional conflicts pose risks to business continuity, employee availability (reserve duty), and supply chains.
- Regulatory and Clinical: Success depends on regulatory approvals for cell therapies (PLX-PAD, PLX-R18, MAIT cells) and cultivated food products. Clinical trial results are not guaranteed.
- Nasdaq Compliance: The company previously received a deficiency letter regarding stockholders' equity but regained compliance in May 2025. It also temporarily lacked a compliant Audit Committee following a director departure but regained compliance in September 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline of cash burn and the status of discussions with the EIB regarding the €20 million loan due in June 2026.
- Capital Raising: Review the terms and status of the "Offering" and "Second Offering" completed in early 2025, and assess the likelihood of future dilutive equity raises.
- CDMO Revenue Sustainability: Confirm the backlog and renewal rates of CDMO contracts, which drove the majority of the revenue increase.
- Geopolitical Impact: Assess the current operational status of the Haifa facility and any disruptions caused by the conflict in the Middle East.
- Grant Funding: Monitor the status of non-dilutive grants from the Israel Innovation Authority (IIA) and Horizon Europe, particularly following the NIAID contract termination.